Benzinga | Oct 4, 2021 07:14AM EDT

Adicet To Present Preclinical Data From Allogeneic Gamma Delta T Cell Platform At SITC 36th Annual Meeting

Adicet Bio, Inc. (NASDAQ:ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the Company will present data in the form of a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting to be held November 10-14, 2021.

Details of the poster presentation:

Title: ADI-002: an IL-15 armored allogeneic "off-the-shelf" V?1 gamma delta CAR T cell therapy for solid tumors targeting glypican-3 (GPC3)

Abstract number: 119

Date: November 12-14, 2021

Poster viewing session: 7:00am - 5:00pm ET